Clinical Trial Update: Investigation on Appropriate Duration of Dabigatran Use After Catheter Ablation for Paroxysmal Atrial Fibrillation in Patients With Low Thromboembolic Risk [Phase 3]

View source ↗

Summary

A Phase 3 clinical trial is investigating the optimal duration of dabigatran after catheter ablation in patients with paroxysmal atrial fibrillation at low thro…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Atrial Fibrillation
• Thromboembolism

Drugs mentioned

• Dabigatran (Dabigatran etexilate)

Snippet

Sponsor: Korea University | Conditions: Atrial Fibrillation, Thromboembolism | Phase 3 | Status: UNKNOWN